Literature DB >> 23872860

Update on the diagnosis and classification of ILD.

Christopher J Ryerson1, Harold R Collard.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to provide an update on the diagnosis and classification of interstitial lung disease (ILD), with a specific focus on newly described ILD subtypes and phenotypes. In addition, the strengths and limitations of the current approach to ILD diagnosis and management are discussed. RECENT
FINDINGS: Idiopathic pleuroparenchymal fibroelastosis and acute fibrinous and organizing pneumonia are new entities that have been described in small case series. Undifferentiated connective tissue disease-associated ILD, smoking-related interstitial fibrosis, familial ILD, unclassifiable ILD, and subclinical ILD have also been better characterized in recent publications. New data regarding these conditions are summarized in this review. The multidisciplinary approach to ILD is reviewed, and complementary classification schemes are described that may help direct the management and improve prognostication of some ILDs.
SUMMARY: ILDs are a large and heterogeneous group of diseases with several newly characterized subtypes and phenotypes. The current approach to ILD classification has limitations in some patients that can be minimized by considering complementary classification schemes.

Entities:  

Mesh:

Year:  2013        PMID: 23872860     DOI: 10.1097/MCP.0b013e328363f48d

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  22 in total

1.  European Respiratory Society International Congress best abstract preview from the allied respiratory professionals from assembly 9.

Authors:  Jason Blonshine; Joana Cruz; Andreja Sajnic; Jana De Brandt
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Interstitial Pneumonia with Autoimmune Features.

Authors:  Bridget A Graney; Aryeh Fischer
Journal:  Ann Am Thorac Soc       Date:  2019-05

3.  [Current classification of interstitial pulmonary diseases].

Authors:  J Vogel-Claussen; A Prasse
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

Review 4.  [Radiological features of interstitial lung diseases].

Authors:  Sabine Dettmer; Sarah Scharm; Hoen-Oh Shin
Journal:  Pathologe       Date:  2021-01-26       Impact factor: 1.011

5.  Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis.

Authors:  Maria Molina-Molina; Michael Kreuter; Vincent Cottin; Tamera J Corte; Frank Gilberg; Klaus-Uwe Kirchgaessler; Judit Axmann; Toby M Maher
Journal:  Front Med (Lausanne)       Date:  2022-06-17

Review 6.  The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases.

Authors:  Caroline V Cotton; Lisa G Spencer; Robert P New; Robert G Cooper
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

Review 7.  Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.

Authors:  So-My Koo; Soo-Taek Uh
Journal:  Korean J Intern Med       Date:  2017-06-30       Impact factor: 2.884

8.  Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study.

Authors:  Onofre Moran-Mendoza; Thomas Ritchie; Sharina Aldhaheri
Journal:  BMJ Open Respir Res       Date:  2021-07

Review 9.  State of the art in the diagnosis and management of interstitial lung disease.

Authors:  Maria T A Buzan; Carmen Monica Pop
Journal:  Clujul Med       Date:  2015-04-15

Review 10.  Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights.

Authors:  Paola Faverio; Federica De Giacomi; Luca Sardella; Giuseppe Fiorentino; Mauro Carone; Francesco Salerno; Jousel Ora; Paola Rogliani; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Grazia Messinesi; Alberto Pesci; Antonio Esquinas
Journal:  BMC Pulm Med       Date:  2018-05-15       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.